Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)Retained EarningsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pharming (PHAR) Other Accumulated Expenses (2019 - 2023)

Historic Other Accumulated Expenses for Pharming (PHAR) over the last 5 years, with Q3 2023 value amounting to -$10.9 million.

  • Pharming's Other Accumulated Expenses fell 4510604.68% to -$10.9 million in Q3 2023 from the same period last year, while for Sep 2023 it was -$10.9 million, marking a year-over-year decrease of 4510604.68%. This contributed to the annual value of -$8.7 million for FY2022, which is 25707058.82% down from last year.
  • As of Q3 2023, Pharming's Other Accumulated Expenses stood at -$10.9 million, which was down 4510604.68% from -$6.0 million recorded in Q2 2023.
  • Pharming's Other Accumulated Expenses' 5-year high stood at $14.7 million during Q2 2021, with a 5-year trough of -$12.6 million in Q2 2022.
  • For the 5-year period, Pharming's Other Accumulated Expenses averaged around -$880584.2, with its median value being -$10976.0 (2021).
  • As far as peak fluctuations go, Pharming's Other Accumulated Expenses crashed by 39850535.25% in 2022, and later soared by 5211.39% in 2023.
  • Quarter analysis of 5 years shows Pharming's Other Accumulated Expenses stood at $4.1 million in 2019, then tumbled by 99.87% to $5175.7 in 2020, then tumbled by 57.63% to $2193.0 in 2021, then crashed by 398505.35% to -$8.7 million in 2022, then dropped by 24.93% to -$10.9 million in 2023.
  • Its Other Accumulated Expenses stands at -$10.9 million for Q3 2023, versus -$6.0 million for Q2 2023 and -$8.7 million for Q4 2022.